Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levobupivacaine is a long-acting amino-amide local anesthetic and the single S-enantiomer of bupivacaine. It produces local and regional anesthesia or analgesia by reversibly inhibiting voltage-gated ion channels, principally voltage-gated sodium channels, thereby preventing initiation and propagation of peripheral nerve action potentials. It is administered as a preservative-free solution for infiltration, peripheral nerve block, epidural anesthesia and analgesia, intrathecal anesthesia, and selected ophthalmic blocks. Levobupivacaine has been marketed as **Chirocaine** and has also been evaluated extensively as a regional anesthetic component in perioperative studies, including breast-cancer surgery; these studies concern analgesia rather than direct treatment of cancer. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20997_CHIROCAINE_prntlbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levobupivacaine.